Chemotherapy with High-Dose Cytosine Arabinoside and Mitoxantrone for Poor-Prognosis Myeloid Leukemias

References

• Champlin R, Gale R P. Acute myelogenous leukemia: Recent advances in therapy. Blood 1987; 69: 1551–1562
   PubMed Web of Science ®Google Scholar
• Cheson B D, Cassileth P A, Head D R, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Weisdorf D J, Oken M M, Johnson G J, et al. Chronic myelodys-plastic syndrome: Short survival with or without evolution to acute leukemia. Br J Haematol 1983; 55: 691–700
   PubMed Web of Science ®Google Scholar
• Champlin R E, Golde D W. Chronic myelogenous leukemia: Recent advances. Blood 1985; 65: 1039–1047
   PubMed Web of Science ®Google Scholar
• Champlin R E, Gajewski J L, Golde D W. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989; 16: 51–56
   PubMed Web of Science ®Google Scholar
• Herzig R H, Wolff S N, Lazarus H W, et al. High-dose cytosine ar-abinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
   PubMed Web of Science ®Google Scholar
• Herzig R H, Lazarus H M, Wolff S N, et al. High-dose cytosine ar-abinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 992–997
   PubMed Web of Science ®Google Scholar
• Phillips G L, Reece D E, Shepherd J D, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–1435
   PubMed Web of Science ®Google Scholar
• Hines J D, Mazza J J, Oken M M, et al. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia. Semin Oncol 1987; 14: 37–39
   PubMed Web of Science ®Google Scholar
• Wolff S N, Marion J, Stein R S, et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: A pilot study. Blood 1985; 65: 1407–1411
   PubMed Web of Science ®Google Scholar
• Tricot G, Boogaerts M A. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986; 63: 477–483
   PubMed Web of Science ®Google Scholar
• Preisler H D, Early A P, Raza A, et al. Therapy of secondary acute nonlymphocytic leukemia with cytarabine. N Engl J Med 1983; 308: 21–23
   PubMed Web of Science ®Google Scholar
• Herzig R H, Phillips G L, Lazarus H M, et al. High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treat Rep 1985; 69: 881–883
   PubMedGoogle Scholar
• Bezwoda W R, Bernasconi C, Hutchinson R M, et al. Mitox-antrone for refractory and relapsed acute leukemia. Cancer 1990; 66: 418–422
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F, Catovsky D, Slocombe G, et al. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. Cancer Treat Rep 1987; 71: 161–163
   PubMedGoogle Scholar
• Paciucci P A, Cuttner J, Holland J F. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia (abstract). Semin Oncol 1984; 11(Suppl l)36–40
   PubMedGoogle Scholar
• Prentice H G, Robbins G, Ma D DF, et al. Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 1984; 11(Suppl 1)32–35
   PubMedGoogle Scholar
• Ho A D, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia–An active and well-tolerated regimen. J Clin Oncol 1988; 6: 213–217
   PubMed Web of Science ®Google Scholar
• Ho A D, Brado B, Haas R, et al. Etoposide in acute leukemia. Past experience and future perspectives. Cancer 1991; 67: 281–284
   PubMed Web of Science ®Google Scholar
• Crossley R J. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11(Suppl 1)54–58
   PubMedGoogle Scholar
• Arlin Z A. Current status of mitoxantrone combination chemotherapy programs: A personal view. Leukemia Lymphoma 1990; 1: 301–305
   PubMedGoogle Scholar
• Bennett J M, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Koeffler H P, Golde D W. Chronic myelogenous leukemia–new concepts. Two parts. N Engl J Med 1981; 304: 1201–1209; 1269–1274
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Yeager A M, Kaizer H, Santos G W, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydro-peroxycyclophosphamide. N Engl J Med 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Phillips G L, Shepherd J D, Barnett M J, et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 1991; 9: 1880–1888
   PubMed Web of Science ®Google Scholar
• Bell A J, Hamblin T J, Oscier D G. Circulating stem cell autografts. Bone Marrow Transplant 1986; 1: 103–110
   PubMed Web of Science ®Google Scholar
• Lass J H, Lazarus H M, Reed M D, et al. Topical corticosteroid therapy for corneal toxicity from systematically administered cytarabine. Am J Ophthamol 1982; 94: 617–621
   PubMed Web of Science ®Google Scholar
• Oken M M, Creech R H, Tormey D C, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–665
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G. Statistical Methods in Medical Research, Edition 2. Blackwell Scientific Publications, OxfordUK 1987
   Google Scholar
• Conover W J. Practical Nonparametric Statistics, 2nd ed. Wiley, New York 1980; 229–239
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cy-tosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–749
   PubMed Web of Science ®Google Scholar
• Walters R S, Kantarjian H M, Keating M J, et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677–682
   PubMed Web of Science ®Google Scholar
• Amadori S, Meloni G, Petti M C, et al. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukemia 1989; 3: 112–114
   PubMed Web of Science ®Google Scholar
• Lejeune C, Tubiana N, Gastaut J A, et al. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol 1990; 44: 240–243
   PubMed Web of Science ®Google Scholar
• Martiat P, Ghilain J M, Ferrant A, et al. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukemia: A prospective randomized study. Eur J Haematol 1990; 45: 164–167
   PubMed Web of Science ®Google Scholar
• Paciucci P A, Cuttner J, Holland J F. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol 1990; 35: 22–25
   PubMed Web of Science ®Google Scholar
• Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64: 1812–1818
   PubMed Web of Science ®Google Scholar
• Richard C, Iriondo A, Garijo J, et al. Therapy of advanced myelodysplastic syndrome with aggressive chemotherapy. Oncology 1989; 46: 6–9
   PubMed Web of Science ®Google Scholar
• Leone G, Pagano L, Marra R, et al. Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia. Cancer Treat Rep 1987; 71: 751–753
   PubMedGoogle Scholar
• Tucker J, Thomas A E, Gregory W M, et al. Acute myeloid leukemia in elderly adults. Hematol Oncol 1990; 8: 13–21
   PubMed Web of Science ®Google Scholar
• Copplestone J A, Prentice A G. Acute myeloblastic leukaemia in the elderly. Leukemia Res 1988; 12: 617–625
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Walters R S, Keating M J, et al. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 1988; 62: 672–676
   PubMed Web of Science ®Google Scholar
• Linkesch W, Thaler J, Gattringer C, et al. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/ relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia. Hamatol Bluttransfus 1990; 33: 330–332
   Google Scholar
• Shepherd J D, Reece D E, Klingemann H-G, et al. Acute myeloid leukemia (AML) in patients (pts) over 60: Induction and consolidation therapy with moderate dose cytosine arabinoside, mitoxantrone, and etoposide (abstract). Proc Am Soc Clin Oncol 1991; 10: 228
   Google Scholar